The standard sales pipeline review: AE presents their deals, says "this one's at 80%, this one's at 60%," and the manager nods. The deals don't close at the rates predicted. The forecast misses. Everybody is surprised. Next week the same review happens.

Pipeline fantasy — the persistent overestimation of deal close probability — costs SaaS companies in missed forecasts, poor resource allocation, and sales capacity planning errors. The fix isn't better forecasting software. It's a different deal review process.

The deal review structure that reduces pipeline fantasy:

Start from the customer's decision process, not the AE's estimate. "What does the customer need to do between now and [close date]?" If the answer is "two more internal approvals, a security review, and contract redlines from legal," the question becomes "has each of those steps been initiated, and do we have clear timeline commitments from the prospect on each?" If not, the close date is wrong.

The four questions that reveal deal reality:

  1. What is the compelling event that makes this close by [date]? (If there isn't one, the date is aspirational)
  2. Have we been in an active conversation with the economic buyer in the last 30 days? (If not, we don't know if the deal is alive)
  3. What is the one thing most likely to kill this deal, and what's our plan for it?
  4. What does the champion need from us in the next two weeks to advance it?

Use a consistent qualification framework. MEDDIC, BANT, or any consistent framework — the point is that every deal can be evaluated on the same criteria so pipeline health is comparable across reps.

Review at-risk deals before won deals. The deals that need attention are the at-risk ones. The deals that are tracking well don't need manager time.

Forecast by stage-specific win rate, not by rep confidence. A deal that's been in "late stage" for 45 days should have its probability adjusted down, regardless of what the rep says.

Good deal reviews make bad news visible early. That's the whole point.